$3.1
2.9%
Downside
Day's Volatility :8.51%
Upside
5.78%
12.58%
Downside
52 Weeks Volatility :68.12%
Upside
63.53%
Period | Edap Tms Sa | Index (Russel 2000) |
---|---|---|
3 Months | -40.95% | 0.0% |
6 Months | -58.78% | 0.0% |
1 Year | -50.0% | 0.0% |
3 Years | -48.33% | -22.3% |
Market Capitalization | 115.0M |
Book Value | $1.28 |
Earnings Per Share (EPS) | -0.59 |
PEG Ratio | 90.47 |
Wall Street Target Price | 11.28 |
Profit Margin | -31.7% |
Operating Margin TTM | -38.93% |
Return On Assets TTM | -11.69% |
Return On Equity TTM | -35.48% |
Revenue TTM | 62.0M |
Revenue Per Share TTM | 1.67 |
Quarterly Revenue Growth YOY | 10.6% |
Gross Profit TTM | 24.2M |
EBITDA | -14.5M |
Diluted Eps TTM | -0.59 |
Quarterly Earnings Growth YOY | -0.62 |
EPS Estimate Current Year | -0.59 |
EPS Estimate Next Year | -0.52 |
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Upside of 263.87%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 44.6M | ↑ 9.61% |
Net Income | -384.5K | ↓ 50.37% |
Net Profit Margin | -0.86% | ↑ 1.05% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 49.9M | ↑ 14.62% |
Net Income | 1.7M | ↓ 547.34% |
Net Profit Margin | 3.37% | ↑ 4.23% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 50.7M | ↓ 7.23% |
Net Income | -2.1M | ↓ 212.7% |
Net Profit Margin | -4.09% | ↓ 7.46% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 49.8M | ↑ 5.77% |
Net Income | 791.3K | ↓ 141.08% |
Net Profit Margin | 1.59% | ↑ 5.68% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 58.3M | ↑ 25.06% |
Net Income | -3.1M | ↓ 519.0% |
Net Profit Margin | -5.32% | ↓ 6.91% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 64.6M | ↑ 7.4% |
Net Income | -22.6M | ↑ 607.26% |
Net Profit Margin | -35.05% | ↓ 29.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.8M | ↑ 6.24% |
Net Income | -5.5M | ↓ 31.5% |
Net Profit Margin | -32.64% | ↑ 17.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.5M | ↓ 9.16% |
Net Income | -5.1M | ↓ 8.44% |
Net Profit Margin | -32.9% | ↓ 0.26% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.5M | ↓ 17.8% |
Net Income | -4.2M | ↓ 16.01% |
Net Profit Margin | -33.62% | ↓ 0.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.8M | ↑ 62.82% |
Net Income | -5.4M | ↑ 24.52% |
Net Profit Margin | -25.71% | ↑ 7.91% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 16.3M | ↓ 21.53% |
Net Income | -5.0M | ↓ 6.94% |
Net Profit Margin | -30.49% | ↓ 4.78% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 17.1M | ↑ 5.84% |
Net Income | -6.6M | ↑ 34.78% |
Net Profit Margin | -38.83% | ↓ 8.34% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 55.4M | ↑ 3.93% |
Total Liabilities | 27.0M | ↑ 9.37% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 59.0M | ↑ 8.88% |
Total Liabilities | 28.6M | ↑ 8.13% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 67.1M | ↑ 4.0% |
Total Liabilities | 35.2M | ↑ 12.58% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 87.3M | ↑ 39.92% |
Total Liabilities | 30.7M | ↓ 6.13% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 107.0M | ↑ 30.94% |
Total Liabilities | 31.2M | ↑ 8.53% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 100.0M | ↓ 9.39% |
Total Liabilities | 37.8M | ↑ 17.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 108.2M | ↑ 0.35% |
Total Liabilities | 31.6M | ↓ 12.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 103.4M | ↓ 5.73% |
Total Liabilities | 34.8M | ↑ 8.89% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 99.6M | ↓ 2.16% |
Total Liabilities | 35.4M | ↑ 3.32% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 100.0M | ↓ 1.76% |
Total Liabilities | 37.8M | ↑ 4.44% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 96.9M | ↓ 2.69% |
Total Liabilities | 39.3M | ↑ 4.24% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 88.5M | ↓ 7.79% |
Total Liabilities | 37.2M | ↓ 4.35% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 199.1K | ↓ 105.72% |
Investing Cash Flow | -1.8M | ↓ 22.79% |
Financing Cash Flow | 1.3M | ↓ 58.97% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.2M | ↑ 2071.43% |
Investing Cash Flow | -1.7M | ↓ 2.36% |
Financing Cash Flow | -737.9K | ↓ 156.37% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.4M | ↓ 47.97% |
Investing Cash Flow | -2.4M | ↑ 31.27% |
Financing Cash Flow | 3.9M | ↓ 582.08% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.0M | ↑ 124.84% |
Investing Cash Flow | -1.9M | ↓ 18.55% |
Financing Cash Flow | 22.9M | ↑ 533.11% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.2M | ↓ 168.03% |
Investing Cash Flow | -2.5M | ↑ 45.18% |
Financing Cash Flow | 23.0M | ↑ 7.28% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.1M | ↑ 0.0% |
Investing Cash Flow | -1.2M | ↓ 106.53% |
Financing Cash Flow | 366.0K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.4M | ↓ 11.27% |
Investing Cash Flow | -1.2M | ↑ 0.0% |
Financing Cash Flow | 23.9K | ↓ 93.57% |
Sell
Neutral
Buy
Edap Tms Sa is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Edap Tms Sa | -36.48% | -58.78% | -50.0% | -48.33% | -14.6% |
![]() Cardinal Health, Inc. | 12.1% | -1.67% | 26.17% | 108.06% | 138.72% |
![]() Cencora Inc | -2.54% | -1.12% | 31.87% | 54.16% | 104.7% |
![]() Mckesson Corporation | -18.35% | -4.6% | 20.44% | 145.35% | 250.63% |
![]() Henry Schein, Inc. | 4.62% | -8.52% | -7.25% | -12.43% | 9.9% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Edap Tms Sa | NA | NA | 90.47 | -0.59 | -0.35 | -0.12 | NA | 1.28 |
![]() Cardinal Health, Inc. | 32.4 | 32.4 | 0.96 | 7.36 | 0.0 | 0.03 | 0.02 | -13.17 |
![]() Cencora Inc | 25.65 | 25.65 | 1.33 | 13.61 | 1.88 | 0.03 | 0.01 | 4.7 |
![]() Mckesson Corporation | 22.99 | 22.99 | 1.46 | 27.59 | 0.0 | 0.04 | 0.01 | -13.53 |
![]() Henry Schein, Inc. | 25.77 | 25.77 | 1.54 | 4.75 | 0.07 | 0.04 | NA | 27.64 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Edap Tms Sa | Buy | $115.0M | -14.6% | NA | -31.7% |
![]() Cardinal Health, Inc. | Hold | $27.3B | 138.72% | 32.4 | 0.38% |
![]() Cencora Inc | Buy | $46.3B | 104.7% | 25.65 | 0.65% |
![]() Mckesson Corporation | Buy | $66.8B | 250.63% | 22.99 | 0.94% |
![]() Henry Schein, Inc. | Hold | $8.9B | 9.9% | 25.77 | 2.82% |
Insights on Edap Tms Sa
Revenue is up for the last 2 quarters, 14.99M → 15.87M (in $), with an average increase of 5.5% per quarter
Netprofit is down for the last 2 quarters, -4.57M → -6.16M (in $), with an average decrease of 34.8% per quarter
In the last 1 year, Cencora Inc has given 31.9% return, outperforming this stock by 81.9%
In the last 3 years, Mckesson Corporation has given 54.2% return, outperforming this stock by 102.5%
Soleus Capital Management, L.P.
Morgan Stanley - Brokerage Accounts
Rock Springs Capital Management LP
Archon Capital Management LLC
Federated Hermes Inc
Bruce & Co Inc
global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke
Organization | Edap Tms Sa |
Employees | 307 |
CEO | Mr. Marc Oczachowski |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.10
-1.27%
Keyarch Acquisition Corp
$3.10
-1.27%
Connexa Sports Technologies Inc
$3.10
-1.27%
Us Value Etf
$3.10
-1.27%
First Wave Biopharma Inc
$3.10
-1.27%
Global X Msci Next Emerging
$3.10
-1.27%
Fat Projects Acquisition Corp
$3.10
-1.27%
Capital Link Global Fintech
$3.10
-1.27%
Applied Uv Inc
$3.10
-1.27%